Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab. Issue 5 (26th February 2021)

• Record Type: Journal Article
• Authors: Sutton, Rosemary; Pozza, Luciano Dalla; Khaw, Seong Lin; Fraser, Chris; Revesz, Tom; Chamberlain, Janis; Mitchell, Richard; Trahair, Toby N.; Bateman, Caroline M.; Venn, Nicola C.; Law, Tamara; Ong, Erika; Heatley, Susan L.; McClure, Barbara J.; Meyer, Claus; Marschalek, Rolf; Henderson, Michelle J.; Cross, Siobhan; White, Deborah L.; Kotecha, Rishi S.
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 5(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-02-26
• Subjects: acute lymphoblastic leukaemia -- blinatumomab -- paediatric -- refractory -- relapse; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28922
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: We report on the Australian experience of blinatumomab for treatment of 24 children with relapsed/refractory precursor B‐cell acute lymphoblastic leukaemia (B‐ALL) and high‐risk genetics, resulting in a minimal residual disease (MRD) response rate of 58%, 2‐year progression‐free survival (PFS) of 39% and 2‐year overall survival of 63%. In total, 83% ( n = 20/24) proceeded to haematopoietic stem cell transplant, directly after blinatumomab ( n = 12) or following additional salvage therapy ( n = 8). Four patients successfully received CD19‐directed chimeric antigen receptor T‐cell therapy despite prior blinatumomab exposure. Inferior 2‐year PFS was associated with MRD positivity (20%, n = 15) and in KMT2A ‐rearranged infants (15%, n = 9). Our findings highlight that not all children with relapsed/refractory B‐ALL respond to blinatumomab and factors such as blast genotype may affect prognosis.